Cardio Diagnostics(CDIO.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Cardio Diagnostics
CDIO.US
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform.
1.955 T
CDIO.USMarket value -Rank by Market Cap -/-

Financial Score

23/01/2026 Update
D
BiotechnologyIndustry
Industry Ranking331/397
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-110.70%E
    • Profit Margin-41516.33%E
    • Gross Margin100.00%A
  • Growth ScoreD
    • Revenue YoY-55.78%E
    • Net Profit YoY20.61%B
    • Total Assets YoY96.12%A
    • Net Assets YoY121.14%A
  • Cash ScoreD
    • Cash Flow Margin-0.24%D
    • OCF YoY-55.78%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreA
    • Gearing Ratio7.25%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    CS Diagnostics Corp. Selects DHL for Bulk and Institutional Shipments

    CS Diagnostics Corp. has chosen DHL for bulk and institutional shipments as part of its multi-channel sales strategy for the MEDUSA SDP product. The company aims to distribute MEDUSA SDP through various B2B channels, including hospitals, gyms, schools, and corporate clients, as well as B2C channels like retail stores in the UAE and Germany, online marketplaces, and direct-to-consumer sales via its e-commerce site. This strategy is aligned with their sustainability roadmap and global logistics partnerships.

    marketscreener·
    US
    DHLGY
    -0.80%
    US
    CDIO
    -2.02%
    marketscreener·
    US
    DHLGY
    -0.80%
    US
    CDIO
    -2.02%

    CS Group (OTCQB: CSDX) Announces Multi-Channel Sales Model, Global Logistics Partners, and Sustainable Innovation Roadmap for MEDUSA SDP | CSDX Stock News

    CS Diagnostics Corp. (OTCQB: CSDX) has announced a multi-channel sales strategy for its MEDUSA SDP product, targeting both institutional and consumer markets. The company will utilize partnerships with DHL and FedEx for global logistics. Additionally, CSDX plans to introduce biodegradable wet wipes as part of its sustainability roadmap. The management emphasizes disciplined execution and strategic partnerships to drive growth and innovation in the healthcare sector.

    StockTitan·
    US
    CDIO
    -2.02%
    StockTitan·
    US
    CDIO
    -2.02%

    Cardio Diagnostics Bets On India To Scale AI Heart Diagnostics

    Cardio Diagnostics has partnered with Aimil Ltd. and Dr. Lal PathLabs to introduce the PrecisionCHD test in India, targeting the country's high heart disease rates. This marks Cardio Diagnostics' first international expansion, utilizing AI and epigenetics to detect coronary heart disease from blood samples. The test aims to improve early detection and treatment customization. The integration into Dr. Lal PathLabs' network is underway, with broader deployment expected in 2026. Cardio Diagnostics shares fell 15.77% to $2.35, reaching a new 52-week low.

    benzinga_article·
    US
    CDIO
    -2.02%
    benzinga_article·
    US
    CDIO
    -2.02%

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

    In Wednesday's pre-market session, Ventyx Biosciences (VTYX) shares surged 61.0% to $16.18, with a market cap of $717.1 million. Other gainers included Cardio Diagnostics (CDIO) up 29.27% to $3.82, Bioage Labs (BIOA) up 15.18% to $17.75, and Monte Rosa Therapeutics (GLUE) up 12.49% to $18.01. Conversely, IM Cannabis (IMCC) shares fell 11.6% to $1.3, Ernexa Therapeutics (ERNA) down 9.45% to $1.15, and Atlantic International (ATLN) decreased by 7.37% to $1.76.

    benzinga_article·
    US
    GLUE
    -0.78%
    US
    IMCC
    -0.74%
    US
    VTYX
    +0.79%
    benzinga_article·
    US
    GLUE
    -0.78%
    US
    IMCC
    -0.74%
    US
    VTYX
    +0.79%

    Cardio Diagnostics, Aimil Ltd. and Dr. Lal PathLabs Limited Partner to Launch the PrecisionCHD™ Test in India | CDIO Stock News

    Cardio Diagnostics, Aimil Ltd., and Dr. Lal PathLabs have partnered to launch the PrecisionCHD™ test in India, marking Cardio Diagnostics' first expansion outside the U.S. This test aims to improve detection and management of coronary heart disease (CHD) using AI and epigenetics. The partnership will integrate the test within Dr. Lal PathLabs' network, with a commercial rollout expected in 2026. The collaboration aims to enhance access to advanced cardiovascular diagnostics in India, addressing the growing health concern of CHD.

    StockTitan·
    US
    CDIO
    -2.02%
    StockTitan·
    US
    CDIO
    -2.02%
    © 2026 Longbridge｜Disclaimer